MGMT-transduced CD34+ hematopoietic stem cells

This gene therapy, developed by Indiana University, involves the ex vivo modification of autologous CD34+ peripheral blood hematopoietic stem cells using a retroviral vector to deliver the O6-methylguanine DNA methyltransferase (MGMT) gene. The primary objective of this therapeutic approach is to provide chemoprotection to the hematopoietic system, specifically the bone marrow, during dose-intensified chemotherapy for central nervous system tumors. By overexpressing MGMT—a DNA repair enzyme that removes alkyl groups from the O6 position of guanine—the modified stem cells become resistant to the myelosuppressive effects of alkylating agents such as procarbazine and lomustine (CCNU). This allows for the administration of higher, potentially more effective doses of chemotherapy while minimizing the risk of severe bone marrow toxicity. The transduction process is typically enhanced using fibronectin-assisted methods to improve gene transfer efficiency into the CD34+ cells.

Other names

MGMT gene therapyMGMT-modified CD34+ cellsMGMT-transduced peripheral blood stem cellsgene therapy-Indiana University-central nervous system tumor